Current best practice for bladder cancer: a narrative review of diagnostics and treatments
E Compérat, MB Amin, R Cathomas, A Choudhury… - The Lancet, 2022 - thelancet.com
This Seminar presents the current best practice for the diagnosis and management of
bladder cancer. The scope of this Seminar ranges from current challenges in pathology …
bladder cancer. The scope of this Seminar ranges from current challenges in pathology …
Bladder cancer incidence and mortality: a global overview and recent trends
S Antoni, J Ferlay, I Soerjomataram, A Znaor, A Jemal… - European urology, 2017 - Elsevier
Context Bladder cancer has become a common cancer globally, with an estimated 430 000
new cases diagnosed in 2012. Objective We examine the most recent global bladder cancer …
new cases diagnosed in 2012. Objective We examine the most recent global bladder cancer …
Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation …
RH Mak, D Hunt, WU Shipley, JA Efstathiou… - Journal of Clinical …, 2014 - ascopubs.org
Purpose Multiple prospective Radiation Therapy Oncology Group (RTOG) protocols have
evaluated bladder-preserving combined-modality therapy (CMT) for muscle-invasive …
evaluated bladder-preserving combined-modality therapy (CMT) for muscle-invasive …
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
J Bellmunt, A Orsola, JJ Leow, T Wiegel… - Annals of …, 2014 - annalsofoncology.org
In Europe, an estimated 151 297 new cases of bladder cancer were diagnosed in 2012, with
an age-standardised incidence rate (per 100000 persons) of 17.7 for males and 3.5 for …
an age-standardised incidence rate (per 100000 persons) of 17.7 for males and 3.5 for …
Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology
PE Spiess, N Agarwal, R Bangs, SA Boorjian… - Journal of the National …, 2017 - jnccn.org
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder …
for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder …
Bladder cancer
Bladder cancer is a complex disease associated with high morbidity and mortality rates if not
treated optimally. Awareness of haematuria as the major presenting symptom is paramount …
treated optimally. Awareness of haematuria as the major presenting symptom is paramount …
Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review
G Ploussard, S Daneshmand, JA Efstathiou, HW Herr… - European urology, 2014 - Elsevier
Context Aims of bladder preservation in muscle-invasive bladder cancer (MIBC) are to offer
a quality-of-life advantage and avoid potential morbidity or mortality of radical cystectomy …
a quality-of-life advantage and avoid potential morbidity or mortality of radical cystectomy …
Impact of immune and stromal infiltration on outcomes following bladder-sparing trimodality therapy for muscle-invasive bladder cancer
Background Bladder-sparing trimodality therapy (TMT) is an alternative to radical cystectomy
(RC) for muscle-invasive bladder cancer (MIBC), and biomarkers to inform therapy selection …
(RC) for muscle-invasive bladder cancer (MIBC), and biomarkers to inform therapy selection …
Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United …
Background Radical cystectomy (RC) is a morbid procedure associated with high costs.
Limited population-based data exist on the complication profile and costs of robot-assisted …
Limited population-based data exist on the complication profile and costs of robot-assisted …